# Abiraterone Acetate and Antiandrogen Therapy With or Without Cabazitaxel and Prednisone in Treating Patients With Metastatic, Castration-Resistant Prostate Cancer Previously Treated With Docetaxel

> **NCT03419234** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **ECOG-ACRIN Cancer Research Group** · enrollment: 223 (actual)

## Conditions studied

- Castration Levels of Testosterone
- Castration-Resistant Prostate Carcinoma
- Metastatic Prostate Carcinoma in the Soft Tissue
- Prostate Carcinoma Metastatic in the Bone
- Stage IV Prostate Adenocarcinoma AJCC v7

## Interventions

- **DRUG:** Abiraterone Acetate
- **DRUG:** Androgen deprivation therapy
- **DRUG:** Cabazitaxel
- **DRUG:** Prednisone

## Key facts

- **NCT ID:** NCT03419234
- **Lead sponsor:** ECOG-ACRIN Cancer Research Group
- **Sponsor class:** NETWORK
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2018-04-26
- **Primary completion:** 2024-01-08
- **Final completion:** 2026-04-01
- **Target enrollment:** 223 (ACTUAL)
- **Last updated:** 2026-04-01

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03419234

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03419234, "Abiraterone Acetate and Antiandrogen Therapy With or Without Cabazitaxel and Prednisone in Treating Patients With Metastatic, Castration-Resistant Prostate Cancer Previously Treated With Docetaxel". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT03419234. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*